Article Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Targeted Therapies in Oncology

Release Date: March 3, 2008
Expiration Date: March 3, 2009

Publication Overview

Authors

Davide Melisi,MD; David J. McConkey,Phd

Overview and Purpose

Traditional cytotoxic chemotherapy is believed to kill cancer cells by activation of apoptosis, often as a result of DNA-damage signaling. However, these chemotherapeutic agents also act on normal cells, resulting in toxicities such as myelosuppression. Recent approaches have focused on activating apoptotic pathways specifically in malignant cells. Apoptotic signaling can be initiated by tumor necrosis factorñrelated apoptosis-inducing ligand (TRAIL), which binds to TRAIL receptors 1 and 2; agonistic antibodies to the TRAIL receptors are also in development. Other novel targets include cyclin-dependent kinases, which regulate progression through the cell cycle, Aurora kinases, which ensure proper chromosome separation during mitosis, and poly(ADP-ribose) polymerase-1, which is involved in DNA repair. Agents targeting these molecules are in early-phase clinical trials.

The purpose of this activity is to update physicians on novel targets for anticancer approaches including death receptors, cell-cycle proteins, and DNA repair enzymes.

Target Audience

This activity is intended for medical oncologists involved in the care of patients with solid tumors. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:
  • Discuss the rationale for and current data regarding agents targeting the death receptors in anticancer therapy
  • Discuss the rationale for targeting components of the cell cycle and DNA repair machinery in anticancer therapy
  • Assess the efficacy and safety of novel agents targeting the cell cycle and DNA repair pathways in advanced malignancies
  • Instructions for Participation

    1. Read the following information before beginning the educational activity.
    2. Study the educational activity.
    3. Complete the CME test.
    4. Answer the evaluation questions.
    5. After successful completion of the test and evaluation, you will receive your certificate of credit online.
    • CME credit will be granted for only 1 form of participation, either online or via the printed publication.
    View the Activity
    You will be asked to login
    or create an account.